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Uncoupling protein 2 (UCP2) belongs to the family of mitochondrial carriers. Here, we highlight
recent ﬁndings regarding UCP2 function in the immune system. UCP2 controls immune cell activa-
tion by modulating MAPK pathways and the production of mitochondrial reactive oxygen species. In
several models of infection, inﬂammation and autoimmunity, a regulatory impact of UCP2 was dem-
onstrated by its direct implication in the production of cytokines and nitric oxide and in cell migra-
tion. In addition, UCP2 is reported as a key protein for oxidation of fatty acids, glutamine and
glucose. Therefore we present a model of how the regulation of nutrient oxidation by UCP2 pro-
motes immune cell activation.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mitochondria are involved in key processes of cellular life such
as cell metabolism, the production of reactive oxygen species (ROS)
and programmed cell death. To fulﬁl their functions, the family of
carrier proteins present in the inner mitochondrial membrane
tightly controls substrate exchange between the cytoplasm and
the mitochondrial matrix. One subfamily comprises the uncou-
pling proteins (UCP) [1–5]. The family member UCP1, speciﬁcally
expressed in brown adipose tissue, is responsible for the thermo-
genic activity of this tissue [1–5]. Since 1997, several UCP1 homo-
logue genes were discovered in mammals, ﬁsh and birds [6]. One of
them shares 60% protein sequence homology with UCP1 and since
ﬁrst experiments suggested an uncoupling activity, it was named
UCP2 [7].
UCP2 is expressed in various tissues including spleen, lung,
intestine, brain, pancreatic islets and white adipose tissue. Con-
trarily to UCP1 whose half-life is close to 30 h, half-life of UCP2chemical Societies. Published by E
ncephalomyelitis; IFN, inter-
nthase; IP10, IFN-inducible
CP1, monocyte chemotactic
; MIG, monokine induced by
r-activated receptor-gamma
ll-like receptor; TNF, tumor
peis less than 1 h [8] and its synthesis is tightly controlled at the
translational level [9]. Ten years of intensive research revealed a
critical role for UCP2 in the control of mitochondrial ROS produc-
tion [10,11]. Moreover, a crucial implication of UCP2 in various
physiological events such as insulin secretion, obesity, diabetes
or neuronal activity was highlighted [12–15] and extensively dis-
cussed [1–5,16,17].
Numerous immune cells including macrophages express UCP2
[18] and its functional implication in immune cell activity was
demonstrated in a broad variety of diseases from atherosclerosis
to inﬂammatory and infectious diseases in mice and humans. The
present review aims ﬁrst to summarize the ﬁndings on the func-
tion of UCP2 during the immune response. Additionally, in regard
to recent data about UCP2 activity in mitochondrial oxidation pro-
cesses, we here present a model explaining how UCP2 might con-
trol mitochondrial metabolism during macrophage activation. By
this way, we seek to draw the attention on the link between
metabolism and immune cell activation.
2. UCP2 deﬁciency favours macrophage activity
Accumulating evidence indicates a crucial role of UCP2 during
immune responses. Early studies focused on the implication of
UCP2 in macrophage activity. Ucp2-deﬁcient macrophages had a
better capacity to eliminate Toxoplasma gondii and Salmonella
typhimurium in vitro thanks to a higher oxidative burst compared
to wild-type (WT) macrophages [11]. In contrast, elimination oflsevier B.V. All rights reserved.
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phagocytosis, L. monocytogenes escapes from vacuoles into the
cytoplasm in less than 30 min [19]. Although the higher oxidative
burst allows the elimination of T. gondii in Ucp2-knock out (KO)
macrophages, it is not sufﬁcient to get rid of L. monocytogenes. It
should be mentioned that the difference in anti-microbial activity
was independent of the ability to phagocytose [11,18].
Upon lipopolysaccharide (LPS) stimulation, Ucp2 deﬁciency
promoted the expression of the inducible form of the NO synthase,
nitric oxide (NO) and ROS production as well as the release of pro-
inﬂammatory cytokines in macrophages [20,21]. Moreover, we re-
ported that monocyte chemotactic protein-1 (MCP1)-induced
transmigration of Ucp2-KO macrophages through endothelial cell
monolayers is increased [21]. These results are well in line with
the ﬁndings of a clearly diminished NO production of LPS-stimu-
lated UCP2-overexpressing macrophages [22], which also dis-
played reduced transmigratory capacity [23].3. UCP2 is involved in macrophage signalling
For years it is accepted that UCP2 controls ROS production and
macrophage activity [11]. However, mechanistic explanation for
the impact of UCP2 on ROS-dependent NO or cytokine production
was lacking.
Moreover, the importance of ROS signalling in macrophage/im-
mune cell activation is well known. NADPH oxidase and mitochon-
dria take part in the ROS-mediated activation of MAP kinases
(MAPK) and NF-jB in response to LPS [24–26].
In the case of UCP2, several groups demonstrated that UCP2
negatively controls mitochondrial ROS production in macrophages
[20,21,27,28], an inhibitory effect absolutely independent of
NADPH oxidase [20,27,28]. Furthermore the involvement of UCP2
in Toll-like receptor4 (TLR4)-induced ROS signalling was evidenced
in primary cultures of macrophages. Upon stimulation by LPS,
UCP2 was quickly downregulated by JNK and p38 pathways. The
consequence was an enhanced mitochondrial ROS production that
stimulated both p38 and ERK pathways as a positive feedback sig-
nal [21]. Thus, decrease of UCP2 levels is a required phenomenon
to promote mitochondrial ROS-dependent MAPK signalling during
macrophage activation. The same signalling events involving UCP2,
mitochondrial ROS, ERK and p38 induction were conﬁrmed in hu-
man melanoma cells [29]. Lately, mitochondrial ROS-dependent
ERK activation was also reported in Ucp2-KO mast cells [30]. These
results conﬁrmed that mitochondria are crucially implicated in
LPS-induced signalling events, introducing UCP2 as a key player
in this context.
In addition enhanced NF-jB activation was reported in spleen
of LPS-treated Ucp2-KOmice due to higher mitochondrial ROS pro-
duction [20]. Finally overexpression of UCP2 in macrophages de-
creased intracellular ROS levels and reduced their immune
activity [22,23], in line with results obtained when ROS signalling
is chemically repressed [25,31,32].4. UCP2 and the immune response
The implication of UCP2 in immunity was evidenced in several
patho-physiological conditions, such as infection, autoimmunity
and inﬂammatory diseases.
Ucp2-KOmice exhibited increased resistance to microbial infec-
tions compared to Ucp2-WT mice. Although the phenotype was
slight with L. monocytogenes [18], the difference was striking with
T. gondii. Actually all Ucp2-KO mice survived the infection con-
trarily to the controls [11]. In a murine model of atherosclerosis,
i.e. a LDL receptor-null genetic background, Ucp2-KO mice devel-
oped larger and more unstable atherosclerotic plaques than WTmice [33]. Regarding autoimmunity, Ucp2-KO mice developed
higher disease scores than Ucp2-WT mice in experimental autoim-
mune encephalomyelitis (EAE), a murine model of multiple sclero-
sis [34]. In addition, the development of type 1 diabetes was
strongly accelerated in UCP2-deﬁcient mice in the model of multi-
ple low-dose of streptozotocin [35].
4.1. Cytokine production
Following listerial infection, increased levels of interleukin-1b
(IL-1b), IL-6 and interferon-c (IFN-c) were observed in Ucp2-KO
mice [18]. These cytokines as well as tumor necrosis factor-a
(TNF-a) were also increased in the spleen of LPS-treated Ucp2-
KO mice [20]. During EAE, CD4+ T lymphocytes from immunized
Ucp2-KO mice produced higher levels of TNF-a and IL-2 [34]. In
autoimmune diabetes, inﬁltrated Ucp2-KO macrophages were
responsible for increased levels of IL-1b in pancreatic islets [35].
On the other hand, the inﬂuence of UCP2 on cytokine production
was conﬁrmed in UCP2-overexpressing transgenic mice, which
displayed lower basal levels of IL-4 and IL-6 compared to WT mice.
In addition, the increase of IL-4 and IL-6 after LPS injection was
lower in UCP2-transgenic mice compared to WT littermates [36].
Furthermore Ucp2-KO mast cells exhibited greater histamine re-
lease and IL-6 production while overexpression of UCP2 induced
an opposite effect [30].
4.2. Immune cell recruitment
Enhanced recruitment of macrophages was noticed in the
spleen of Ucp2-KO mice after L. monocytogenes infection and in
pancreatic islets in autoimmune diabetes [18,35]. During L. mono-
cytogenes infection, levels of MCP1 were strongly increased in
Ucp2-KO mice [18] giving a possible explanation for enhanced im-
mune cell recruitment. No changes in MCP1 levels were observed
in autoimmune diabetes, suggesting that the better macrophage
recruitment into pancreatic islets in this situation was a conse-
quence of increased UCP2-stimulated migration capacity of macro-
phages [21,23]. However the implication of other chemokines
more relevant in the context of autoimmune diabetes, such as
IFN-inducible protein 10 and monokine induced by IFN-c, cannot
be excluded. A higher amount of inﬁltrating macrophages was also
observed in atherosclerotic plaques of Ucp2-KO mice [33] and in
spinal cord during EAE [34]. Unfortunately, chemokine levels were
not evaluated in these studies.5. UCP2 and adaptative immunity
In addition to macrophages, UCP2 is expressed in dendritic cells,
mastocytes, neutrophils but also B and T lymphocytes [18,30]. For
instance UCP2 downregulation in response to LPS was also ob-
served in dendritic cells [37] but was not investigated during lym-
phocyte activation.
In autoimmune diabetes, inﬁltration of lymphocytes into pan-
creatic islets was more important in Ucp2-KO mice, suggesting a
role of UCP2 in the adaptive response [35]. However macrophages,
the ﬁrst cells that accumulate in islets, are mandatory for subse-
quent lymphocytic insulitis and b-cell destruction [38]. In that
way massive arrival of highly inﬂammatory macrophages into is-
lets of Ucp2-KO mice upon diabetes induction results in an acute
inﬂammation [35]. This strongly deleterious event is responsible
for b-cell destruction. In atherosclerosis, although more macro-
phages were observed in atherosclerotic plaques of Ucp2-KO mice,
the number of lymphocytes was similar in both genotypes [33].
In EAE, T- and B-cell responses were modiﬁed. In absence of
UCP2, the proliferation of T cells from immunized mice was in-
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IgG, assessing the B-cell response, was increased in Ucp2-deﬁcient
mice [34]. However since IL-2 production was also enhanced in
Ucp2-KOmice [34], one can suggest that differences in T- and B-cell
responses may result from a higher local IL-2 stimulation rather
than by a direct inﬂuence of UCP2 on lymphocyte proliferation.
Taken together, there are no clear indications that UCP2 directly
affects lymphocyte activation.
6. Human genomic
Human genetic analyses on the 866G/A polymorphism in the
promoter of Ucp2 reinforce the results in animal studies. The G al-
lele is associated with a lower expression of UCP2 in both lympho-
cytes and macrophages when compared to the A allele [39]. This
polymorphism modulates the development of diabetic neuropathy
in type 1 diabetic patients whereby the G allele favours the disease
[40]. The G allele was also associated with susceptibility to multi-
ple sclerosis [39], asymptomatic carotid atherosclerosis [41] as
well as with several inﬂammatory diseases such as rheumatoid
arthritis, systemic lupus erythematosus, Wegener’s granulomato-
sis, Churg-Strauss syndrome, Crohn’s disease and ulcerative colitis
[42]. Moreover, the 866G/A polymorphism was associated with
inﬂammatory markers (e.g. ﬁbrinogen, C3 and C4) in Swedish chil-
dren and adolescents [43]. However no correlation was found be-
tween this polymorphism and primary sclerosing cholangitis or
psoriasis [42].7. Frommetabolism to signalling: modulation of mitochondrial
oxidation by UCP2
One important question remains to be answered: how does
UCP2 modulate mitochondrial ROS production and consequently
trigger signalling cascades?
In a cerebral ischemic model, UCP2 was proposed as a regulator
of mitochondrial glutathione levels [44]. The authors suggested
that UCP2-mediated regulation of ROS production could result
from the regulation of mitochondrial GSH levels in this model
[44]. However, whereas UCP2 controls the mitochondrial ROS
(superoxide anion) production [21,28,30,45], superoxide dismu-
tase levels are unchanged in macrophages [11]. To be more precise,
higher oxidative state of Ucp2-KO mice was responsible of their
overall lower antioxidant response in diet-induced atherosclerosis
[46] and to impaired pancreatic beta-cell function [47].
Mitochondrial respiration is coupled to the phosphorylation of
ADP. However an uncoupled state is achieved when respiration
does not depend on ATP synthesis. One consequence of mitochon-
drial uncoupling is a decrease in mitochondrial ROS production
and UCP2 was proposed to be a key mediator of this phenomenon
[17,48]. For a complete review on the mechanisms of UCP2-medi-
ated uncoupling, please refer to Brand et al. and Krauss et al.
[17,49]. However existing data about an uncoupling activity of
UCP2 are full of controversies [2–4,50–54], possibly due to ﬂawed
experimental conditions when analyzing a proton transport activ-
ity of UCP2.An alternative to uncoupling activity of UCP2 could be
metabolic: UCP2 is implicated in the choice of the substrate oxi-
dized by mitochondria [55,56]. In that case, presence of UCP2 de-
creases the oxidation of glucose-derived pyruvate [55,56] while it
favours the oxidation of other substrates such as fatty acids and
glutamine (Fig. 1).
Actually we showed in macrophages that UCP2 is mandatory for
efﬁcient mitochondrial oxidation of glutamine, a strong inducer of
UCP2 expression [51,57], without uncoupling activity [51]. In
mouse embryonic ﬁbroblasts, UCP2 increases fatty acid oxidation
and promotes the metabolic shift from glucose oxidation to fattyacid oxidation also without uncoupling activity [52]. Similarly,
UCP2 is responsible for the metabolic switch from glucose to fatty
acid oxidation during starvation in hypothalamic neurons. In that
case UCP2 mediates loss of glucose sensing [13]. These three obser-
vations of UCP2-dependent modulation of mitochondrial oxidation
cannot be explained by a proton transport activity. There is still no
clear data available on a physiologic substrate transported by
UCP2. Although it remains to be identiﬁed, taking into account
these important reports [13,51,52], it was hypothesized that
UCP2 could direct pyruvate out of the mitochondria or avoid the
conversion of glucose-derived pyruvate to acetyl-CoA [55,56].
7.1. Glucose metabolism and mitochondrial ROS
Basically, the production of mitochondrial ROS results from the
escape of electrons from the respiratory chain (Box 1) and hence
depends on the ﬂow of electrons in the respiratory chain. Accord-
ing to the metabolic hypothesis, UCP2 controls the oxidation of
glucose-derived pyruvate and thereby the speed of the Krebs cycle.
This implies that UCP2 regulates electron entry into the respiratory
chain. Consequently, UCP2 modulation of glucose oxidation may be
a way to control mitochondrial ROS production in absence of any
uncoupling activity. Thus, in this model, UCP2-mediated regulation
of mitochondrial ROS production is completely indirect and may
account for each UCP2-expressing cell type.Box 1. Oxidative phosphorylation and mitochondrial ROS
production.
Mitochondria are the powerhouses of the cell, converting
energy into ATP during a phenomenon called oxidative
phosphorylation.
Basically, glycolysis leads to the formation of pyruvate from
glucose in the cytoplasm. In the mitochondrial matrix, pyru-
vate is transformed in acetyl-CoA which enters the Krebs cycle.
The Krebs cycle furnishes NADH, H+ and FADH2 to the respira-
tory chain. Reoxidation of these coenzymes provides electrons
to the respiratory chain. A set of redox reactions transports the
electrons through different membrane complexes to complex
IV where they are transferred to oxygen as ﬁnal acceptor. In
the same time, protons are pumped from the mitochondrial
matrix to the intermembrane space, creating an electro-chem-
ical gradient on either side of the inner membrane. This gradi-
ent is necessary for the phosphorylation of ADP into ATP by the
F0–F1 ATP synthase.
However during these events some electrons escape from
the respiratory chain and combine with oxygen, resulting in
superoxide anion formation. This phenomenon takes place
mainly at complexes I and III; other minor mitochondrial
ROS sources being the a-keto-glutarate deshydrogenase of
the Krebs cycle and the monoamine oxidase. The speed of
the respiratory chain is absolutely crucial. Indeed if slow, the
half-life of intermediaries increases and so does the production
of ROS.
Therefore, mitochondrial ROS production depends on the
activity the respiratory chain, i.e. the entry/ﬂow of electrons
in the respiratory chain and consequently on the metabolic
status of the cell.7.2. Model of macrophage activation (Fig. 2)
The activation of macrophages involves profound transcrip-
tional and translational modiﬁcations, leading among others to
changes in cellular metabolism [58,59]. In resting macrophages,
Fig. 1. UCP2 inhibits glucose oxidation. UCP2 expression is induced by glutamine and fatty acids. UCP2 is necessary for efﬁcient glutamine and fatty acid oxidation while it
decreases glucose oxidation. In this way UCP2 participates in the ‘‘choice’’ of the substrates used by the mitochondrion.
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fatty acids [60,61]. High UCP2 expression levels in resting macro-
phages allow intense glutamine and fatty acid oxidation. Upon
LPS activation UCP2 is rapidly downregulated [21,22] and cellular
use of glucose is considerably increased while glutamine oxidation
is unchanged [58,62,63]. In the same time, fatty acid utilisation is
decreased and directed away from mitochondrial oxidation [61].
This is in accordance with the assumption that UCP2 downregula-
tion favours mitochondrial glucose oxidation. The increase of glu-
cose oxidation thus enhances mitochondrial ROS production and
potentiates MAPK activation [21]. In this way, glutamine and fatty
acids are spared from mitochondrial oxidation in macrophages
upon LPS stimulation. So they can be used for other purposes inFig. 2. UCP2 during macrophage activation. (A) In resting macrophages, UCP2 is high
Following LPS stimulation, oxidation of glucose is strongly increased contrarily to glu
expression by p38 and JNK is required for efﬁcient glucose oxidation. Consequently th
mitochondrial ROS production and MAPK activation.the cytoplasm than energy production, such as biomolecule syn-
thesis or generation of second messengers.8. Concluding remarks
Deﬁciency of UCP2 in immune cells has important conse-
quences in the development of the immune response. It should
be mentioned that many conclusions results from the comparison
of Ucp2-KO and -WT mice. Therefore compensatory mechanisms
cannot be ruled out, as for all studies with knockout mice. How-
ever, the variety of experimental approaches (knockout mice, over-
expressing mice and transient overexpressing systems) resulted inly expressed. The mitochondrion oxidizes glucose, glutamine and fatty acids. (B)
tamine and fatty acid oxidation. Actually we propose that the inhibition of UCP2
e ﬂow of electrons in the respiratory chain is affected, leading to an increase of
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fectly fair.
To date, the role of UCP2 in macrophages was only studied dur-
ing classical activation. Interestingly, fatty acid oxidation is en-
hanced in alternatively activated macrophages via Stat6 and
peroxisome proliferator-activated receptor-gamma coactivator1
(PGC1) [58]. Since UCP2 is required for fatty acid oxidation [52]
and PGC1 is a known inducer of UCP2 [64], the role of UCP2 in
alternatively activated macrophages should be investigated in
the future in more detail. Understanding of the molecular implica-
tions of UCP2 in metabolic pathways and their transcriptional reg-
ulation affecting immune cell activation may be an asset for the
conception of future therapies for chronic inﬂammatory diseases.
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